Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis

J Neurol Sci. 2016 Jul 15:366:229-233. doi: 10.1016/j.jns.2016.04.054. Epub 2016 May 6.

Abstract

Background: Atrophy of subcortical grey matter structures has been reported to be associated with clinical measures of disability in multiple sclerosis (MS) patients. It is not clear if the degree of tissue loss in patients with very early MS is associated with changes in disability measures.

Objective: To study the association between subcortical grey matter structure volumes and clinical disability outcomes.

Methods: Relapsing MS patients within 12months of clinical onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36months of follow-up and serial brain MRI and clinical assessments. MRI metrics, including thalamic, putamen, caudate, pallidum and cerebellar cortical volume, were measured by an automated, custom-made FreeSurfer pipeline. Volumes were normalized for head size. Clinical measures included EDSS, MSFC scores and its components. Mixed model regression measured time trends and associations between imaging and clinical outcomes.

Results: 42 patients with a mean follow-up of 30.6months were analyzed in this study. There was a statistically significant decrease in thalamus, caudate and putamen volumes, but not cerebellar cortical and pallidum volumes during the follow-up period. Baseline thalamus, caudate and putamen volumes predicted subsequent changes in the timed 25-ft walk test (p=0.036) and MSFC (p=0.024). There was a trend for an association between baseline caudate volume and subsequent change in the timed 25-ft walk test (p=0.084). No association between baseline imaging and subsequent EDSS changes were seen.

Conclusion: Subcortical grey matter volumes at early stages of MS are associated with subsequent changes in disability measures.

Keywords: Ambulation; Atrophy; Grey matter; Multiple sclerosis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Atrophy
  • Brain / diagnostic imaging*
  • Cross-Sectional Studies
  • Disability Evaluation
  • Disease Progression
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Gray Matter / diagnostic imaging*
  • Humans
  • Interferon beta-1a / therapeutic use
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / diagnostic imaging*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / physiopathology*
  • Neuroprotective Agents / therapeutic use
  • Organ Size
  • Prognosis
  • Riluzole / therapeutic use
  • Walking* / physiology

Substances

  • Adjuvants, Immunologic
  • Neuroprotective Agents
  • Riluzole
  • Interferon beta-1a